PMID- 20336594
OWN - NLM
STAT- MEDLINE
DCOM- 20100622
LR  - 20131121
IS  - 2040-3429 (Electronic)
IS  - 1472-4472 (Linking)
VI  - 11
IP  - 4
DP  - 2010 Apr
TI  - Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 
      diabetes mellitus.
PG  - 455-63
AB  - Dutogliptin (PHX-1149T), being developed by Phenomix Corp, Forest Laboratories 
      Inc and Chiesi Farmaceutici SpA, is a small-molecule dipeptidyl peptidase-4 
      (DPP-4) inhibitor for the potential oral treatment of type 2 diabetes mellitus 
      (T2DM). DPP-4 quickly degrades the insulin secretory hormones, glucose-dependent 
      insulinotropic peptide and glucagon-like peptide-1; thus inhibiting the 
      degradation of these hormones is a viable treatment option for patients with 
      T2DM. In preclinical studies, dutogliptin potently inhibited DPP-4 and, in a 
      model of T2DM, treatment with dutogliptin improved glucose homeostasis. 
      Pharmacokinetic analyses in animals, healthy individuals and patients with T2DM 
      demonstrated that drug exposure increased in a dose-dependent manner. Results 
      from phase II clinical trials indicated that once-daily dutogliptin, in 
      combination with other oral diabetes therapies, reduces postprandial blood 
      glucose and HbA1c levels, both indicators of successful diabetes management. In 
      phase I and II trials, dutogliptin was safe, well tolerated and associated with 
      extremely low rates of hypoglycemia. At the time of publication, phase III trials 
      were underway and the results of these will be imperative to determine the 
      efficacy of dutogliptin compared with other small molecule DPP-4 inhibitors, such 
      as sitagliptin and vildagliptin.
FAU - Johnson, Kathryn M S
AU  - Johnson KM
AD  - Beloit College, Department of Biology, Beloit, WI 53511, USA. 
      johnsonkms@beloit.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Blood Glucose)
RN  - 0 (Protease Inhibitors)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Blood Glucose/*metabolism
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/blood/chemically induced/*drug therapy
MH  - Gastric Inhibitory Polypeptide/therapeutic use
MH  - Glucagon-Like Peptide 1/blood/metabolism/*therapeutic use
MH  - Glucose/*therapeutic use
MH  - Humans
MH  - Protease Inhibitors/*therapeutic use
RF  - 58
EDAT- 2010/03/26 06:00
MHDA- 2010/06/23 06:00
CRDT- 2010/03/26 06:00
PHST- 2010/03/26 06:00 [entrez]
PHST- 2010/03/26 06:00 [pubmed]
PHST- 2010/06/23 06:00 [medline]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2010 Apr;11(4):455-63.